

RECEIVED TO 05 JUN 2006



Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065
Patent Department

Facsimile Cover Sheet

TODAY'S DATE: 6/5/06

PLEASE DELIVER THE FOLLOWING MESSAGE TO:

Examiners Name: Paulette R. Kidwell

Examiner's fax number: (571) 270-9881

Group number: _____

THIS MESSAGE IS FROM:

Name: David A. Rubin

Phone No.: (732) 594-2675

Mail Location: RY60-30

Fax No.: (732) 594-4720

RE: Applicants: Abbadie, et al.

Case No.: 21156YP

Serial No.: 10/559,701

Filed: 6/2/2004

Title: CCR-2 ANTAGONISTS FOR TREATMENT OF
NEUROPATHIC PAIN

NUMBER OF PAGES BEING TRANSMITTED (INCLUDING COVER): 10

**IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL
(732) 594-0516**

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile
transmitted to the Patent and Trademark Office on the
date shown below

Kathleen A. Reynolds

Type or print name of person signing certification

Kathleen A. Reynolds
Signature

June 5, 2006

Date

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants:	Catherine Abbadie, et al.	
Serial No.:	10/559,701	Case No.: 21156YP
Filed:	June 2, 2004	
For:	CCR-2 ANTAGONISTS FOR TREATMENT OF NEUROPATHIC PAIN	

Art Unit:

Examiner:

Mail Stop Missing Parts
The Honorable Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

COMMUNICATION RESPONSIVE TO NOTIFICATION OF MISSING REQUIREMENTS

This Communication is in response to the "Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US)" mailed April 6, 2006. Applicants point out that all inventor declarations were submitted to the USPTO on December 6, 2005 with the National Phase paperwork. (See attached copies of declarations, and copy of postcard noting "Two (2) executed original declarations.") In the telephonic conversation between David Rubin and Paulette R. Kidwell on June 5, 2006, Ms. Kidwell confirmed receipt of these declarations.

Serial No. 10/559,701
Case No. 21156YP
Page 2

Because the declarations were properly submitted it is believed that no fees are due.
However, the USPTO is authorized to charge any appropriate fee(s) to Deposit Acct. 13-2755.

Respectfully submitted,

By: 

David Rubin
Reg. No. 40,314
Attorney for Applicants

Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065-0907
(732) 594-2675

Date: June 5, 2006

THE PATENT & TRADEMARK OFFICE ACKNOWLEDGES, AND HAS
STAMPED HEREON, THE DATE OF THE RECEIPT AND THE ASSIGNED
SERIAL NUMBER OF THE FOLLOWING PATENT APPLICATION:

CASE NUMBER	DATE	ATTORNEY	EXPRESS MAIL <input checked="" type="checkbox"/>
21156YP	Dec 6, 2005	David Rubin	EV 660605252 US
TITLE CCR-2 ANTAGONISTS FOR TREATMENT OF NEUROPATHIC PAIN			
INVENTORS Catherine Abbadie, Jill Ann Lindia, Hao Wang		10/559701	
NO. OF PAGES 296	NO. OF CLAIMS 4	PAGES OF DRAWING 0	
DECLARATIONS IDS sent w/ copy of 1 reference Two (2) executed original declarations		ACCOUNT CHARGE 13 - 2755 \$ 1,600.00	

F1071.3 REV.9/95

RECEIVED USPTO DEC 2005